Sanara MedTech Inc. Approves MiMedx Merger in Special Meeting

What Happened
Sanara MedTech Inc. announced that its shareholders approved the Agreement and Plan of Merger with MiMedx Group, Inc. at a special meeting held after a definitive proxy was filed on September 4, 2026. A quorum was present; the vote approves the merger (Merger Sub to merge into Sanara, leaving Sanara as a wholly owned MiMedx subsidiary) and a non‑binding advisory vote on merger‑related executive compensation also passed.

Key Details

• Record date: September 1, 2026; outstanding common shares: 9,188,035.
• Shares present or represented: 6,411,427 (≈69.78% of outstanding).
• Proposal 1 (approve Merger Agreement): For 6,372,989; Against 1,944; Abstain 36,494.
• Proposal 2 (non‑binding advisory approval of merger‑related executive compensation): For 5,841,470; Against 75,247; Abstain 494,710.
• HSR update: Initial HSR filings were made Aug 12, 2026; MiMedx withdrew and refiled on Sept 15, 2026, restarting the 30‑calendar‑day waiting period that now expires at 11:59 p.m. ET on Oct 15, 2026 (unless extended).

Why It Matters
Shareholder approval is a major contractual step toward closing the acquisition by MiMedx, but the transaction still requires regulatory clearance under the HSR Act and satisfaction or waiver of other conditions in the Merger Agreement. Retail investors should note the timeline: regulatory review is the next material milestone (HSR waiting period currently set to expire Oct 15, 2026). The advisory vote on executive compensation passed but is non‑binding.